KAT6A and acute myeloid leukemia: Further studies in AML demonstrated that MOZ-TIF2 reduced CBP activity in vivo, resulting in aberrant acetylation patterns that inhibited transcriptional activities of critical cell cycle regulators, such as p53 [74].